The novel gluconeogenesis inhibitor FR225654, isolated from the culture broth of Phoma sp. No. 00144, has an unique structure that consists of a highly oxygenated trans-decalin ring and a b -keto-enol, with a characteristic side chain. This compound selectively inhibited gluconeogenesis of rat primary hepatocytes and had hypoglycemic effects in several in vivo mouse models.
Introduction
In diabetes, hepatic glucose production is accelerated as a result of insulin resistance or insulin deficiency [1] . This phenomenon results in high blood glucose levels that cause many of the complications of this disease [2] . One way to control diabetes may be to inhibit this upregulated hepatic glucose production, specifically by inhibition of gluconeogenesis. Therefore, we screened microbial products for gluconeogenesis inhibitors using primary cultured rat hepatocytes. We isolated FR225654 from the culture broth of Phoma sp. fungal strain No. 00144 [3] . This compound has a highly oxygenated trans-decalin ring, a b -keto-enol in the core decalin moiety, and a characteristic side chain possessing a conjugated carboxylic acid and a tri-substituted olefin [4] . In this paper, we report its inhibitory activity both in vitro and in vivo.
Materials and Methods

Materials
Glucagon, insulin, and streptozotocin (STZ) were purchased from Sigma-Aldrich (St. Louis, MO, USA). The Glucose C-II test Wako was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). A plasma insulin ELISA kit was purchased from Shibayagi Co., Ltd. (Gunma, Japan).
In Vitro Glucose Consumption Assay
To measure glycolysis, we used a glucose consumption assay using ddY mouse whole blood cells. Whole mouse blood was diluted 1 : 10 with FR225659-containing Dulbecco's Modified Eagle's Medium lacking glucose and incubated at 37°C in a humidified incubator (95% air, 5% CO 2 ) for 1 hour. After centrifugation, the glucose levels in the supernatant were determined enzymatically (Glucose C-II test Wako, Wako Pure Chemical Industries, Ltd).
In Vitro Glycogenolysis Assay
To measure glycogenolysis, we used two simple methods with cultured rat primary hepatocytes. First, hepatocytes were isolated from fed Wistar rats by the method described in the accompanying paper [3] . Isolated hepatocytes were J. Antibiot. 58 (7) hours. After incubation, cells were washed twice with phosphate-buffered saline and subjected to two rounds of freeze-thaw. Amyloglucosidase (2.5 units/ml) was added and the solution incubated at 37°C for 2 hours. Glucose, originating from glycogen, was measured enzymatically.
Assay for Enzymatic Activity
The methods for measuring the activity of glucose-6-phosphatase (G6Pase) and fructose-1,6-bisphosphatase (FBPase) have been described previously [5, 6] . We used rat liver microsomes and cytosol as the source of G6Pase and FBPase, respectively. The activity of glycogen synthase kinase-3 was measured using a commercially available enzyme (Glycogen synthase kinase-3 beta, Sigma-Aldrich) and substrate (GS-2 peptide, Upstate Biotechnology, Charlottesville, VA, USA).
Animals
Male C57BL/6N mice were purchased from Charles River Japan Inc. (Atsugi, Japan). Male C57BL/KsJ-db/db mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA).
Male 6-week old ddY mice, purchased from Japan SLC Inc. (Shizuoka, Japan), were made diabetic by intraperitoneal injection of a bolus of streptozotocin (STZ; 225 mg/kg) dissolved in 2 mM citrate buffer (pH 4.5). After 10 days, plasma glucose levels were determined using the Glucose C-II test Wako (Wako Pure Chemical Industries, Ltd., Osaka, Japan). Animals with levels Ͼ400 mg/dl were selected for the study.
The glucagon-induced mouse hyperglycemia model has been described previously [7] .
In all experiments, FR225654 was dissolved in PEG-400 and given orally at a volume of 10 ml/kg.
Statistical Analysis of in Vivo Experiments
Data are expressed as meansϮSEM. Statistical analysis was conducted using an unpaired Student's t-test or a oneway ANOVA.
Results
Inhibition of Gluconeogenesis in Vitro
FR225654 strongly inhibited gluconeogenesis from pyruvate in cultured primary rat hepatocytes in vitro (Table  1) . This compound also inhibited gluconeogenesis when glycerol was added to the culture medium as a gluconeogenesis substrate (data not shown). These results indicate that FR225654 inhibited gluconeogenesis downstream from aldolase. However, FR225654 did not affect glycogenolysis in hepatocytes. Furthermore, this compound did not affect glycolysis since the consumption of glucose by blood cells was not inhibited in the presence of high concentrations of this compound (Table 1 ).
Consequentially, we tested the ability of FR225654 to inhibit glucose-6-phosphatase and fructose-1,6-bisphosphatase which are key enzymes in the gluconeogenesis pathway, and glycogen synthase kinase-3 which is a key enzyme in glycogen synthesis. However, the activities of these enzymes were not affected by FR225654, even in the presence of high concentrations of this compound (Table 1) .
In Vivo Hypoglycemic Effects of FR225654
We examined the acute hypoglycemic activity of FR225654 on C56BL/6N mice. Peripheral blood glucose was significantly decreased by 3 hours after oral administration at a dose of 10 mg/kg FR225654. In contrast, plasma insulin levels were unchanged (Fig. 1) .
To examine whether this hypoglycemic activity was due to the inhibition of hepatic glucose production, we tested the effects of FR225654 in a glucagon-induced hyperglycemia mouse model. In this model, glucagon leads to uncontrolled increase of hepatic glucose production. FR225654 significantly suppressed glucagon-induced hyperglycemia in mice (Fig. 2) . Next, we examined the effects of FR225654 in an experimental type 1 diabetic mouse model, STZ-treated mice. FR225654 significantly decreased the peripheral blood glucose levels of STZ-treated mice at a dose of 10 mg/kg (Fig. 3) . Furthermore, we examined the effects of FR225654 in a spontaneous type 2 diabetic mouse model, the db/db mice, which are characterized by severe insulin resistance and increased hepatic glucose production. The peripheral blood glucose levels of these mice showed a significant decrease in the dose dependent manner following oral administration of FR225654 (Fig. 4) .
In all experiments, this compound brought on severe hypoglycemia at a dose of 32 mg/kg. Also, the hypoglycemic effects of this compound (10 mg/kg) were turned back to normal glucose levels after refeeding and overnight period (data not shown).
Discussion
Hepatic glucose production, especially through the gluconeogenesis pathway, is reported to be continuously upregulated in diabetes [8] . Therefore a gluconeogenesis inhibitor which normalizes the inappropriate upregulation of hepatic glucose production is a very useful agent in the treatment of diabetes. This hypothesis is supported by the fact that an inhibitor of fructose-1,6-bisphosphatase has hypoglycemic effects in animal models and type 2 diabetic subjects [9] .
We have screened gluconeogenesis inhibitors from microbial products using primary cultured hepatocytes, and identified a novel gluconeogenesis inhibitor FR225654 from the culture broth of Phoma sp. No. 00144 [3] . FR225654 showed a potent inhibition of gluconeogenesis in primary cultures of rat hepatocytes. FR225654 specifically inhibited gluconeogenesis, especially in the downstream of the aldolase reaction, and did not affect glycolysis or glycogenolysis. We have not yet identified the molecular target of this compound.
FR225654 had potent plasma glucose-lowering effects in several mouse models. These effects were independent of insulin action, because FR225654 did not alter plasma insulin levels in normal mice and had potent hypoglycemic effects in STZ-mice, which are a toxin induced insulindeficient mouse model. These data raise the possibility that this insulin-independent hypoglycemic compound could be used in treatment of obesity induced diabetes, or for control of glucose levels in type 1 diabetes.
We examined short-term in vivo experiments because we have screened rapidly acted inhibitor of gluconeogenesis using the assay system of primary cultured hepatocytes. However, it is continuously exploring the long-term effects and toxicity of this compound, now.
In summary, we used primary cultures of rat hepatocytes to screen extracts from fungal cultures and found a novel gluconeogenesis inhibitor, FR225654. This compound displays a potent inhibition of gluconeogenesis and had potent plasma glucose-lowering effects in several animal models. We are continuing to characterize the inhibitory mechanism of this compound.
